Recent investigations have focused on the intersection of GLP|GIP|glucagon receptor activator therapies and dopamine neurotransmission. While GIP activators are widely employed for treating type 2 diabetes, their unexpected impacts on reward circuits, specifically governed by DA systems, are gain